China IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.8% during the forecast period. With the huge number of smokers in China, rapid industrialization, and changing lifestyles, the rate of IBD prevalence is estimated to increase in the recent decade. These factors further raise the risk of IBD and contribute to the rising demand for diagnosis and treatment solutions thus creating a significant market in the country. According to the World Bank, China had reported 49.2% of total males, smokes regularly in 2014, while the figure was 48.7% and 48.4% in 2015 and 2016 respectively. Smoking causes an adverse effect on small and large intestines, which as a result increasing the prevalence rate of IBD in China.

Request a Free Sample of our China Inflammatory Bowel Disease (IBD) Therapeutics Market: https://www.omrglobal.com/request-sample/china-ibd-inflammatory-bowel-disease-therapeutics-market

China IBD therapeutics market is segmented on the basis of disease type and treatment type. The disease type segment includes ulcerative colitis and Crohn’s disease. Crohn’s disease segment is estimated to dominate the market. The growth of the segment is attributed to the comparatively higher incidence of Crohn’s disease than ulcerative colitis. For Crohn’s and ulcerative colitis, the development of minimally invasive methods has been evolved with more caution as compared to other colorectal diseases. This is primarily due to disease-related characteristics that are concerned with IBD. The treatment type segment is further segmented into anti-inflammatory drugs and surgery. There is a range of anti-inflammatory drugs used for the treatment of IBD, such as immunosuppressants (methotrexate, ciclosporin, and azathioprine), steroids and biological drugs. Steroids are commonly referred to as Corticosteroids. This enables to reduce inflammation in the digestive tract and provides relief from symptoms of IBD condition. For several people, corticosteroids have a potential anti-inflammatory effect that starts working very rapidly.
A full Report of China Inflammatory Bowel Disease (IBD) Therapeutics Market is Available at: https://www.omrglobal.com/industry-reports/china-ibd-inflammatory-bowel-disease-therapeutics-market

China Inflammatory Bowel Disease IBD Therapeutics Market Segmentation

By Disease Type

• Ulcerative Colitis
• Crohn’s Disease

By Treatment Type

• Surgery
• Anti- Inflammatory Drug Administration
• Steroids
• Immunosuppressant
• Biological Drugs
• Amino salicylates
• Others
Company Profiles

• AbbVie Inc.
• Allergan, PLC
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Co. Ltd.
• Eli Lilly and Co.
• Johnson & Johnson Services Inc.
• Mercator Pharmaceutical Solutions
• Pfizer Inc.
• RPG Life Sciences Ltd.
• Sanofi S.A.
• Takeda Pharmaceutical Co., Ltd.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-ibd-inflammatory-bowel-disease-therapeutics-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit Orion Market Research

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +1 646-755-7667, +91 7803040404